ArchiMed takes Esperion Therapeutics private for $1.1bn
The take-private adds a commercial-stage biopharma platform to ArchiMed, anchored by therapies for cardiometabolic and rare/orphan diseases, including lipid-lowering treatments.
Takeaways
- Esperion Therapeutics is a Develops cardiometabolic and rare/orphan disease therapies.
- ArchiMed is acquiring Esperion Therapeutics.
- The business serves Cardiometabolic and rare/orphan disease therapies.
ArchiMed has taken Esperion Therapeutics private in a $1.1 billion deal, acquiring a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies.
Esperion develops treatments for lipid management and cardiovascular risk reduction, addressing conditions with significant unmet medical need.
ArchiMed is a healthcare-dedicated private equity firm that has been active in pharma and medtech.
The firm previously acquired IRAB, a Barcelona-based developer and producer of PET radiopharmaceuticals for clinical diagnosis and research.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.